HOUSTON — Cannabidiol is all the buzz at this year’s American Epilepsy Society Annual Meeting thanks to positive data from several placebo-controlled trials in patients with Lennox-Gastaut and Dravet syndromes.

Neurology Advisor caught up with Justin Gover, CEO of GW Pharmaceuticals, which is now operating as Greenwich Biosciences in the United States, to discuss the results of the latest trials and what they may mean for the status of cannabidiol as the company continues to push forward towards a New Drug Application with the US Food and Drug Administration for its product Epidiolex®.

Watch the video below and read more about the positive, placebo-controlled trials here:

Continue Reading

Topics:

AES 2016 Dravet Syndrome Epilepsy Lennox-Gastaut Syndrome Seizure Disorders